Two new oral disease modifying therapies in relapsing remitting multiple sclerosis

被引：0
作者：
Lebrun, C. [1 ]
de Seze, J. [2 ]
机构：
[1] Hop Louis Pasteur, Serv Neurol, F-06002 Nice 1, France
[2] Hop Hautepierre, Serv Neurol, F-67000 Strasbourg, France
来源：
REVUE NEUROLOGIQUE | 2014年 / 170卷 / 12期
关键词：
PLACEBO-CONTROLLED PHASE-3; DOUBLE-BLIND; TERIFLUNOMIDE; TRIAL; BG-12;
D O I：
10.1016/j.neurol.2014.11.002
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：721 / 722
页数：2
相关论文
共 50 条
  • [31] The effect of disease modifying therapies on fatigue in multiple sclerosis
    Rivera, Samantha Cruz
    Aiyegbusi, Olalekan Lee
    Meier, Daniela Piani
    Dunne, Achille
    Harlow, Danielle E.
    Henke, Christian
    Kamudoni, Paul
    Calvert, Melanie J.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 79
  • [32] Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method
    Guger, Michael
    Enzinger, Christian
    Leutmezer, Fritz
    Kraus, Joerg
    Kalcher, Stefan
    Kvas, Erich
    Berger, Thomas
    JOURNAL OF NEUROLOGY, 2020, 267 (07) : 2090 - 2100
  • [33] Disease-modifying therapies for multiple sclerosis: Focus on future direction
    Wilbanks, Jennifer
    FORMULARY, 2012, 47 (11) : 392 - 399
  • [34] Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis
    Tselis, Alex
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2010, 11 (05) : 577 - 585
  • [35] Laquinimod in the treatment of relapsing remitting multiple sclerosis
    Hainke, Undine
    Thomas, Katja
    Ziemssen, Tjalf
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (06) : 701 - 709
  • [36] Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis
    Calabrese, M.
    Bernardi, V.
    Atzori, M.
    Mattisi, I.
    Favaretto, A.
    Rinaldi, F.
    Perini, P.
    Gallo, P.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (04) : 418 - 424
  • [37] Multiple sclerosis hospitalizations among users of oral disease-modifying therapies
    Nguyen, Thanh Phuong Pham
    Jacobs, Dina
    Thibault, Dylan
    Willis, Allison W.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 52
  • [38] Disease-modifying therapies for multiple sclerosis
    De Angelis, Floriana
    John, Nevin A.
    Brownlee, Wallace J.
    BMJ-BRITISH MEDICAL JOURNAL, 2018, 363
  • [39] Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis
    Guarnera, Cristina
    Bramanti, Placido
    Mazzon, Emanuela
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 2193 - 2207
  • [40] Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis
    Papadopoulos, Dimitrios
    Mitsikostas, Dimos-Dimitrios D.
    CNS DRUGS, 2018, 32 (11) : 1069 - 1078
12345